Temporal trends in evidence supporting therapeutic interventions in heart failure and other European Society of Cardiology guidelines

被引:1
作者
Canepa, Marco [1 ,2 ,7 ,8 ]
De Marzo, Vincenzo [2 ]
Ameri, Pietro [1 ,2 ]
Ferrari, Roberto [3 ,4 ]
Tavazzi, Luigi [4 ,5 ]
Rapezzi, Claudio [5 ]
Porto, Italo [1 ,2 ]
Maggioni, Aldo Pietro [6 ]
机构
[1] Osped Policlin San Martino IRCCS, Cardiol Unit, Genoa, Italy
[2] Univ Genoa, Dept Internal Med, Genoa, Italy
[3] MTA Grp, Sci Dept, Lugano, Switzerland
[4] Azienda Osped Univ Ferrara Arcispedale S Anna, Ferrara, Italy
[5] Maria Cecilia Hosp, GVM Care & Res, Cotignola, Italy
[6] Heart Care Fdn, Ctr Studi ANMCO, Florence, Italy
[7] Univ Genoa, Dept Internal Med, Cardiovasc Unit, Cardiol, Genoa, Italy
[8] Osped Policlin San Martino IRCCS, Viale Benedetto 15,10, GE-16132 Genoa, Italy
来源
ESC HEART FAILURE | 2023年 / 10卷 / 05期
关键词
Guideline; Level of evidence; Heart failure; Randomized controlled trial; Temporal trend; ACUTE PULMONARY-EMBOLISM; TASK-FORCE; CLINICAL-TRIALS; ESC GUIDELINES; DIAGNOSIS; ASSOCIATION; MANAGEMENT; LESSONS;
D O I
10.1002/ehf2.14459
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsThis study aimed to determine whether any change occurred over time in level of evidence (LoE) of therapeutic interventions supporting heart failure (HF) and other European Society of Cardiology guideline recommendations. Methods and resultsWe selected topics with at least three documents released between 2008 and April 2022. Classes of recommendations (CoR) and supporting LoE related to therapeutic interventions within each document were collected and compared over time. A total of 1822 recommendations from 18 documents on 6 topics [median number per document = 112, 867 (48%) CoR I] were included in the analysis. There was a trend towards a reduction over time in the percentage of CoR I in HF (46-36-34%), non-ST elevation myocardial infarction (NSTEMI; 78-58-54%), and pulmonary embolism (PE; 65-50-39%) guidelines, with a decrease in the total number of recommendations for HF only. Percentage of CoR I was stable over time around 40% for valvular heart disease (VHD) and atrial fibrillation (AF), and around 60% for cardiovascular prevention (CVP), with an increase in the total number of recommendations for VHD and CVP and a decrease for AF. Among CoR I, 319 (37%) were supported by LoE A, with a decrease over time for HF (56-46-42%), an increase for NSTEMI (29-38-48%) and AF (28-31-36%), a bimodal distribution for PE and CVP, and a lack for VHD. ConclusionsLoE supporting therapeutic recommendations in contemporary European guidelines is generally low. Physicians should be aware of these limitations, and scientific societies promote a greater understanding of their significance and drive future research directions.
引用
收藏
页码:3019 / 3027
页数:9
相关论文
共 50 条
  • [1] Empagliflozin in Heart Failure with a Preserved Ejection Fraction
    Anker, Stefan D.
    Butler, Javed
    Filippatos, Gerasimos
    Ferreira, Joao P.
    Bocchi, Edimar
    Boehm, Michael
    Brunner-La Rocca, Hans-Peter
    Choi, Dong-Ju
    Chopra, Vijay
    Chuquiure-Valenzuela, Eduardo
    Giannetti, Nadia
    Gomez-Mesa, Juan Esteban
    Janssens, Stefan
    Januzzi, James L.
    Gonzalez-Juanatey, Jose R.
    Merkely, Bela
    Nicholls, Stephen J.
    Perrone, Sergio V.
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sim, David
    Spinar, Jindrich
    Squire, Iain
    Taddei, Stefano
    Tsutsui, Hiroyuki
    Verma, Subodh
    Vinereanu, Dragos
    Zhang, Jian
    Carson, Peter
    Lam, Carolyn Su Ping
    Marx, Nikolaus
    Zeller, Cordula
    Sattar, Naveed
    Jamal, Waheed
    Schnaidt, Sven
    Schnee, Janet M.
    Brueckmann, Martina
    Pocock, Stuart J.
    Zannad, Faiez
    Packer, Milton
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) : 1451 - 1461
  • [2] [Anonymous], 2021, Eur Heart J, V42, P1908, DOI 10.1093/eurheartj/ehaa895
  • [3] Baumgartner H, 2018, EUR HEART J, V39, P1980, DOI [10.1093/eurheartj/ehx636, 10.1093/eurheartj/ehx391]
  • [4] Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines
    Bayes-Genis, Antoni
    Aimo, Alberto
    Metra, Marco
    Anker, Stefan
    Seferovic, Petar
    Rapezzi, Claudio
    Castiglione, Vincenzo
    Nunez, Julio
    Emdin, Michele
    Rosano, Giuseppe
    Coats, Andrew J. S.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (06) : 916 - 926
  • [5] The Evidence Supporting Cardiovascular Guidelines Is There Evidence of Progress in the Last Decade?
    Bonow, Robert O.
    Braunwald, Eugene
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (11): : 1053 - 1054
  • [6] Assessing the Gold Standard - Lessons from the History of RCTs
    Bothwell, Laura E.
    Greene, Jeremy A.
    Podolsky, Scott H.
    Jones, David S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (22) : 2175 - 2181
  • [7] Camm AJ, 2010, EUR HEART J, V31, P2369, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350]
  • [8] CLELAND JG, 1995, EUR HEART J, V16, P741
  • [9] An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure
    Cleland, John G.
    Abraham, William T.
    Linde, Cecilia
    Gold, Michael R.
    Young, James B.
    Daubert, J. Claude
    Sherfesee, Lou
    Wells, George A.
    Tang, Anthony S. L.
    [J]. EUROPEAN HEART JOURNAL, 2013, 34 (46) : 3547 - +
  • [10] Real-World Evidence - Where Are We Now?
    Concato, John
    Corrigan-Curay, Jacqueline
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (18) : 1680 - 1682